Esteva FJ - Search Results

1

The HER-2-targeting antibodies trastuzumab and pertuzumab synergistically inhibit the survival of breast cancer cells.

Nahta R, Hung MC, Esteva FJ. Nahta R, et al. Among authors: esteva fj. Cancer Res. 2004 Apr 1;64(7):2343-6. doi: 10.1158/0008-5472.can-03-3856. Cancer Res. 2004. PMID: 15059883

2

Locally advanced breast cancer.

Esteva FJ, Hortobagyi GN. Esteva FJ, et al. Hematol Oncol Clin North Am. 1999 Apr;13(2):457-72, vii. doi: 10.1016/s0889-8588(05)70065-4. Hematol Oncol Clin North Am. 1999. PMID: 10363140 Review.

3

Chemo-signal therapy, an emerging new approach to modify drug resistance in breast cancer.

Pusztai L, Esteva FJ, Cristofanilli M, Hung MC, Hortobagyi GN. Pusztai L, et al. Among authors: esteva fj. Cancer Treat Rev. 1999 Oct;25(5):271-7. doi: 10.1053/ctrv.1999.0132. Cancer Treat Rev. 1999. PMID: 10544071 Review.

4

Phase II trial and pharmacokinetic evaluation of cytosine arabinoside for leptomeningeal metastases from breast cancer.

Esteva FJ, Soh LT, Holmes FA, Plunkett W, Meyers CA, Forman AD, Hortobagyi GN. Esteva FJ, et al. Cancer Chemother Pharmacol. 2000;46(5):382-6. doi: 10.1007/s002800000173. Cancer Chemother Pharmacol. 2000. PMID: 11127942

5

Trastuzumab in combination with chemotherapy for the treatment of metastatic breast cancer.

Fornier M, Esteva FJ, Seidman AD. Fornier M, et al. Among authors: esteva fj. Semin Oncol. 2000 Dec;27(6 Suppl 11):38-45; discussion 92-100. Semin Oncol. 2000. PMID: 11236027 Review.

6

Chemotherapy of metastatic breast cancer: what to expect in 2001 and beyond.

Esteva FJ, Valero V, Pusztai L, Boehnke-Michaud L, Buzdar AU, Hortobagyi GN. Esteva FJ, et al. Oncologist. 2001;6(2):133-46. doi: 10.1634/theoncologist.6-2-133. Oncologist. 2001. PMID: 11306725 Free article. Review.

7

Weekly trastuzumab and paclitaxel therapy for metastatic breast cancer with analysis of efficacy by HER2 immunophenotype and gene amplification.

Seidman AD, Fornier MN, Esteva FJ, Tan L, Kaptain S, Bach A, Panageas KS, Arroyo C, Valero V, Currie V, Gilewski T, Theodoulou M, Moynahan ME, Moasser M, Sklarin N, Dickler M, D'Andrea G, Cristofanilli M, Rivera E, Hortobagyi GN, Norton L, Hudis CA. Seidman AD, et al. Among authors: esteva fj. J Clin Oncol. 2001 May 15;19(10):2587-95. doi: 10.1200/JCO.2001.19.10.2587. J Clin Oncol. 2001. PMID: 11352950 Clinical Trial.

8

Expression of erbB/HER receptors, heregulin and P38 in primary breast cancer using quantitative immunohistochemistry.

Esteva FJ, Hortobagyi GN, Sahin AA, Smith TL, Chin DM, Liang SY, Pusztai L, Buzdar AU, Bacus SS. Esteva FJ, et al. Pathol Oncol Res. 2001;7(3):171-7. doi: 10.1007/BF03032345. Pathol Oncol Res. 2001. PMID: 11692142 Free article.

9

Lack of activity of stealth liposomal doxorubicin in the treatment of patients with anthracycline-resistant breast cancer.

Rivera E, Valero V, Esteva FJ, Syrewicz L, Cristofanilli M, Rahman Z, Booser DJ, Hortobagyi GN. Rivera E, et al. Among authors: esteva fj. Cancer Chemother Pharmacol. 2002 Apr;49(4):299-302. doi: 10.1007/s00280-001-0405-3. Epub 2001 Dec 18. Cancer Chemother Pharmacol. 2002. PMID: 11914909

10

Phase II study of weekly docetaxel and trastuzumab for patients with HER-2-overexpressing metastatic breast cancer.

Esteva FJ, Valero V, Booser D, Guerra LT, Murray JL, Pusztai L, Cristofanilli M, Arun B, Esmaeli B, Fritsche HA, Sneige N, Smith TL, Hortobagyi GN. Esteva FJ, et al. J Clin Oncol. 2002 Apr 1;20(7):1800-8. doi: 10.1200/JCO.2002.07.058. J Clin Oncol. 2002. PMID: 11919237 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

231 results

Search Page

Filters